Biophytis (OTC: BPTSY) forms Hong Kong joint venture with $20M BIO101 plan
Rhea-AI Filing Summary
Biophytis S.A. has submitted the registration filing for its new joint venture in Hong Kong, Biophytis Biopharmaceutical Holding LTD, created with Asian partners including Ronghui Renhe Life Technology. The joint venture is designed to speed up development and commercialization of BIO101 for sarcopenia across Asian markets.
Biophytis will contribute patents and a license to develop and commercialize BIO101 in China, Japan and South Korea, while Asian partners will provide a total committed financing of $20 million, starting with an initial $3 million tranche. After the expected official registration and Closing, the venture plans to launch operations focused on preparing a Phase 3 clinical study of BIO101 in Asia, filing required regulatory applications, and building local teams.
Positive
- None.
Negative
- None.
Insights
Strategic Asia JV links BIO101 rights with $20M committed funding.
Biophytis is formalizing an Asia-focused joint venture in Hong Kong to advance BIO101 in sarcopenia. The company contributes patents and regional commercialization rights, while Asian partners provide a committed financing package, aligning scientific assets with local capital and market access.
The total committed financing of $20 million, with an initial $3 million tranche, is earmarked for clinical and regulatory development of BIO101 toward marketing authorization in Asia. This directly ties funding to late-stage plans, including a Phase 3 clinical study and associated regulatory submissions.
The filing states that official registration is expected within days, with Closing to follow and immediate operational launch thereafter. Execution will hinge on timely regulatory interactions and successful Phase 3 preparation in Asian markets, which future company communications and trial milestones are likely to clarify.
Key Figures
Key Terms
joint venture financial
Phase 3 clinical study medical
marketing authorization regulatory
sarcopenia medical
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Date of report: June 2, 2026
Commission File Number: 001-38974
BIOPHYTIS S.A.
(Translation of registrant’s name into English)
Stanislas Veillet
Biophytis S.A.
Sorbonne University—BC 9, Bâtiment A 4ème étage
4 place Jussieu
75005 Paris, France
+33 1 44 27 23 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On June 2, 2026, Biophytis S.A. issued a press release announcing the submission of the registration filing for its joint venture in Hong Kong. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.
EXHIBIT LIST
| Exhibit | Description | |
| 99.1 | Press Release dated June 2, 2026. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOPHYTIS S.A. | ||
| Date: June 2, 2026 | By: | /s/ Stanislas Veillet |
| Name: Stanislas Veillet | ||
| Title: Chairman and Chief Executive Officer | ||
Exhibit 99.1
BIOPHYTIS STRATEGIC UPDATE: JOINT VENTURE
REGISTRATION FILING SUBMITTED IN HONG KONG
Paris (France) and Cambridge (Massachusetts, U.S.), June 2, 2026, at 7:00 a.m CET. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies impacting longevity, today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily engaged in the manufacturing and distribution of healthcare products.
The joint-venture, named Biophytis Biopharmaceutical Holding LTD, is intended to accelerate the development and commercialization of BIO101 in sarcopenia across Asian markets. This milestone represents a significant and anticipated step in the implementation of Biophytis’ Asian development strategy, in line with the announcements made since the beginning of the year.
“The submission of this registration filing marks a key milestone in the execution of our Asian strategy. It reflects our commitment to establishing a long-term presence in this high-potential region. Biophytis Hong Kong will enable us, together with Ronghui Renhe, to strengthen our ability to make our therapeutic innovations accessible to a greater number of patients, particularly those affected by sarcopenia in China”, said Stanislas Veillet, CEO of Biophytis.
The official registration of the joint venture is expected within the coming days. In the following weeks, the respective contributions of the partners will be made, allowing completion of the transaction (the “Closing”). Biophytis SA will contribute to the joint venture its patents and a license to develop and commercialize BIO101 in China, Japan and South Korea, while the Asian partners will provide the first tranche of the total committed financing of $20 million, representing an initial payment of $3 million. This financing is intended to support the clinical and regulatory development of BIO101 in sarcopenia through marketing authorization in Asia.
The operational launch of the joint venture will take place immediately following the Closing, with a focus on three strategic priorities: preparing the Phase 3 clinical study of BIO101 in sarcopenia in Asia, submitting the regulatory applications required to initiate this study across the region, and recruiting dedicated local teams.
* * *
About Ronghui Renhe
Ronghui Renhe Group is a healthcare conglomerate headquartered in Shenzhen, China, bringing together several subsidiaries active in the pharmaceutical industry, medical devices, dermocosmetics and healthcare equipment sectors, with a significant presence in pharmaceutical distribution and healthcare product manufacturing.
About Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age- related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
Page 1 of 2
Biophytis Contact
Investor relations
investors@biophytis.com
Media relations
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr – +33 6 38 31 90 50
Page 2 of 2